Skip to main content

Dronabinol 2.5 mg capsules (Nausea, vomiting and loss of appetite in AIDS and Cancer patients)

Dronabinol 2.5 mg capsules



Contraindicated: with Metronidazole and Disulfiram

Drug Classes: Antiemitic, Appetite enhancer, Cannabinoid   

FDA approved uses:

Chemotherapy-induced nausea and vomiting

HIV/AIDS - Loss of appetite

AIDS - Loss of appetite

(Capsule) Initial, 2.5 mg orally twice daily, before lunch and dinner; titration, adjust based on optimal clinical response and tolerance; may increase dosage gradually to 2.5 mg before lunch and 5 mg before dinner, and then to 5 mg twice daily as tolerated; MAX, 20 mg/day in divided doses  

Chemotherapy-induced vomiting, In patients with inadequate response to commonly used antiemetic treatments
  • (Capsule) Initial, 5 mg/m(2) orally 1 to 3 hours prior to chemotherapy, then 5 mg/m(2) every 2 to 4 hours after chemotherapy for a total of 4 to 6 doses/day; titration, adjust dosage based on response and tolerance; may increase dose in increments of 2.5 mg/m(2); MAX, 15 mg/m(2)/dose
Side effects:

Serious
  • Immunological hypersensitivity
  • Cardiovascular: Hypotension (1% or less ), Tachycardia (Greater than 1% )
  • Psychiatric: Depression (1% or less ), Mania, Schizophrenia
Non -serious

Gastrointestinal, pain, palpitations, vomiting, anxiety, euphoria and hallucinations

Comments

Post a Comment

Popular posts from this blog

Mounjaro, Is it a game changer for weight loss and diabetes?

  MOUNJARO™ ( Tirzepatide) was approved for medical use in the United States in May 2022 WEIGHT LOSS: (Not approved by FDA for weight loss) Eli Lilly and Company is  finalizing an application to the U.S. Food and Drug Administration for fast-track approval to sell tirzepatide for chronic weight management. MOUNJARO™ is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated in adults for type 2 diabetes mellitus management. CONTRAINDICATIONS Personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2  Known serious all to tirzepatide or any of the excipients in MOUNJARO                                                                    ...
Post a Comment
Read more

Thyroid health- Quality of Life

  Let's get a TSH blood test for our family and friends Normal serum TSH ranges are higher in the  people age 70 to 80 years ; based on this, higher serum TSH goals may be needed as a patient ages.  The American Thyroid Association (ATA) suggests raising the target serum TSH to 4-6 m IU/L for 70 years-old and up The thyroid is a small, butterfly-shaped hormone-producing gland located at the front of the neck. The thyroid gland secretes two main hormones:  thyroxine (T-4) and triiodothyronine (T-3).   These hormones regulate energy levels, metabolism of fats, proteins and carbohydrates, body temperature, heart rate.  Hypothyroidism happens when the underactive thyroid gland doesn't make enough hormones. Hypothyroidism affects up to 10% of the general population (5% undiagnosed) . A n autoimmune disease called Hashimoto's diseas e where our body  makes antibodies that attack healthy thyroid tissues  is the most common cause of hypothyroidism in soc...
Post a Comment
Read more

Vaccines, XBB.1.5 variant and antibody evasion

Corona virus XBB and XBB.1 were first identified in India in mid-August and quickly became predominant in India.  The spike protein of the predominant XBB subvariant has 14 mutations in addition to those found in BA.2, including 5 in the N-terminal domain (NTD) and 9 in the receptor-binding domain (RBD), whereas XBB.1 has an additional G252V mutation. Single and combination therapies with monoclonal antibodies have received emergency use authorization for COVID-19.  Using  COVID-19 pseudovirus, which enables the study of the SARS-CoV-2 virus in cell culture,   XBB, and XBB.1 subvariants were found to have far greater antibody resistance than earlier variants. XBB sublineages are completely resistant to bebtelovimab, leaving us with no authorized antibody for treatment use. The combination of mAbs known as Evusheld that is authorized for the prevention of COVID-19 is also completely inactive against the new subvariants. This poses a serious problem for millions of im...
Post a Comment
Read more